FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980850779> ?p ?o ?g. }

• W2980850779 endingPage "10" @default.
• W2980850779 startingPage "1" @default.
• W2980850779 abstract "The response rate and survival improvement for rituximab, a CD20-targeting monoclonal antibody, have been demonstrated in marginal zone lymphoma (MZL) as monotherapy and in combination with chemotherapeutic regimens, yet relapses still occur despite treatment completion. Thus, extending the period of remission in MZL patients remains an essential goal. This multicenter, single-arm, open-label phase II study evaluated the survival efficacy of 2 years of rituximab-maintenance therapy in patients with stage III-IV CD20-positive MZL who had responded to first-line R-CVP (rituximab, cyclophosphamide, vincristine, and prednisolone). The objective of this study was to determine whether rituximab maintenance following R-CVP warrants further investigation.Prior to rituximab-maintenance therapy, patients received 6-8 cycles of first-line R-CVP therapy for stage III-IV MZL. Rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), and vincristine (1.4 mg/m2; maximum 2 mg) were administered via an intravenous infusion on day 1 of each 3-week cycle, while oral prednisolone (100 mg) was given on days 1-5 of each 3-week cycle. The patients who achieved complete response (CR), partial response (PR), or stable disease (SD) to R-CVP treatment, were prescribed rituximab-maintenance therapy which was administered intravenously at a dose of 375 mg/m2 every 8 weeks for up to 12 cycles. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS) and treatment safety.47 patients were enrolled, of whom, 45 (96%) received rituximab-maintenance treatment. Fifteen (33%) patients had nodal MZL. Following R-CVP first-line therapy, 20 (44%), 22 (49%), and 3 (7%) patients achieved CR, PR, and SD, respectively. After a median follow-up of 38.2 months, their observed 3-year PFS rate was 81%. During the rituximab-maintenance, 6 PR and 1 SD patients achieved CR following the administration of R-CVP. Elevated LDH and the presence of B symptoms were found to be significant prognostic factors for PFS (P = 0.003) and demonstrated a 3-year OS rate of 90%. Rituximab-maintenance therapy was well tolerated, and the common treatment-emergent adverse events were sensory neuropathy (18%), myalgia (13%), fatigue (9%), and neutropenia (9%).Rituximab-maintenance therapy following first-line R-CVP demonstrated good PFS in patients with stage III-IV MZL, in addition to a favorable toxicity profile. Trial registration clinicaltrials.gov: NCT01213095." @default.
• W2980850779 created "2019-10-25" @default.
• W2980850779 creator A5000439099 @default.
• W2980850779 creator A5004166441 @default.
• W2980850779 creator A5012187284 @default.
• W2980850779 creator A5016428936 @default.
• W2980850779 creator A5019303498 @default.
• W2980850779 creator A5020404601 @default.
• W2980850779 creator A5022379369 @default.
• W2980850779 creator A5023660159 @default.
• W2980850779 creator A5028137817 @default.
• W2980850779 creator A5032561728 @default.
• W2980850779 creator A5044268319 @default.
• W2980850779 creator A5044958787 @default.
• W2980850779 creator A5045264210 @default.
• W2980850779 creator A5065500084 @default.
• W2980850779 creator A5066039159 @default.
• W2980850779 creator A5071885891 @default.
• W2980850779 creator A5075932421 @default.
• W2980850779 creator A5078559857 @default.
• W2980850779 creator A5082144323 @default.
• W2980850779 creator A5082389619 @default.
• W2980850779 creator A5088824120 @default.
• W2980850779 date "2019-10-16" @default.
• W2980850779 modified "2023-10-17" @default.
• W2980850779 title "Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study" @default.
• W2980850779 cites W1568270436 @default.
• W2980850779 cites W1729134232 @default.
• W2980850779 cites W1968889356 @default.
• W2980850779 cites W1982790762 @default.
• W2980850779 cites W1989135596 @default.
• W2980850779 cites W1996936382 @default.
• W2980850779 cites W2012804428 @default.
• W2980850779 cites W2013358855 @default.
• W2980850779 cites W2016651883 @default.
• W2980850779 cites W2021363101 @default.
• W2980850779 cites W2029409133 @default.
• W2980850779 cites W2073473826 @default.
• W2980850779 cites W2081935515 @default.
• W2980850779 cites W2097685737 @default.
• W2980850779 cites W2101648653 @default.
• W2980850779 cites W2105813567 @default.
• W2980850779 cites W2107202569 @default.
• W2980850779 cites W2127749132 @default.
• W2980850779 cites W2129623766 @default.
• W2980850779 cites W2133201432 @default.
• W2980850779 cites W2145604368 @default.
• W2980850779 cites W2148613364 @default.
• W2980850779 cites W2156522119 @default.
• W2980850779 cites W2159872381 @default.
• W2980850779 cites W2163435946 @default.
• W2980850779 cites W2164819810 @default.
• W2980850779 cites W2198559016 @default.
• W2980850779 cites W2292975070 @default.
• W2980850779 cites W2304617849 @default.
• W2980850779 cites W2307278666 @default.
• W2980850779 cites W2601380568 @default.
• W2980850779 cites W2608724752 @default.
• W2980850779 cites W2743972848 @default.
• W2980850779 cites W2745122811 @default.
• W2980850779 cites W2809316281 @default.
• W2980850779 cites W2891417930 @default.
• W2980850779 doi "https://doi.org/10.1186/s40880-019-0403-7" @default.
• W2980850779 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6796378" @default.
• W2980850779 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31619290" @default.
• W2980850779 hasPublicationYear "2019" @default.
• W2980850779 type Work @default.
• W2980850779 sameAs 2980850779 @default.
• W2980850779 citedByCount "9" @default.
• W2980850779 countsByYear W29808507792020 @default.
• W2980850779 countsByYear W29808507792021 @default.
• W2980850779 countsByYear W29808507792022 @default.
• W2980850779 countsByYear W29808507792023 @default.
• W2980850779 crossrefType "journal-article" @default.
• W2980850779 hasAuthorship W2980850779A5000439099 @default.
• W2980850779 hasAuthorship W2980850779A5004166441 @default.
• W2980850779 hasAuthorship W2980850779A5012187284 @default.
• W2980850779 hasAuthorship W2980850779A5016428936 @default.
• W2980850779 hasAuthorship W2980850779A5019303498 @default.
• W2980850779 hasAuthorship W2980850779A5020404601 @default.
• W2980850779 hasAuthorship W2980850779A5022379369 @default.
• W2980850779 hasAuthorship W2980850779A5023660159 @default.
• W2980850779 hasAuthorship W2980850779A5028137817 @default.
• W2980850779 hasAuthorship W2980850779A5032561728 @default.
• W2980850779 hasAuthorship W2980850779A5044268319 @default.
• W2980850779 hasAuthorship W2980850779A5044958787 @default.
• W2980850779 hasAuthorship W2980850779A5045264210 @default.
• W2980850779 hasAuthorship W2980850779A5065500084 @default.
• W2980850779 hasAuthorship W2980850779A5066039159 @default.
• W2980850779 hasAuthorship W2980850779A5071885891 @default.
• W2980850779 hasAuthorship W2980850779A5075932421 @default.
• W2980850779 hasAuthorship W2980850779A5078559857 @default.
• W2980850779 hasAuthorship W2980850779A5082144323 @default.
• W2980850779 hasAuthorship W2980850779A5082389619 @default.
• W2980850779 hasAuthorship W2980850779A5088824120 @default.
• W2980850779 hasBestOaLocation W29808507791 @default.
• W2980850779 hasConcept C126322002 @default.
• W2980850779 hasConcept C141071460 @default.

• next